Skip to main content

RAPT Therapeutics, Inc.

RAPTDelisted Mar 3, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001673772

RAPT Therapeutics, Inc. was delisted on Mar 3, 2026; its insiders filed their last Form 4 on Mar 5, 2026; 106 institutions reported holding it in 13F filings for Q4 2025, worth $1.02B in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
106
Q4 2025, +42 vs. previous quarter
13F value
$1.02B
Reported value at the end of Q4 2025
Superinvestors holding
0
At the end of Q4 2025

From SEC filings, in USD.

Revenue, FY2024
–
No comparable prior period
Net income, FY2024
-$129.9M
No comparable prior period
Free cash flow, FY2024
-$83.4M
No comparable prior period
Revenue, Q3 FY2025
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Feb 27, 2026.

Short interest
1.34M
Shares sold short
Change
−902.0K
−40.2% vs. previous
Days to cover
1.39
At average daily volume

Superinvestors holding RAPT, Q4 2025

Go to the superinvestors tab

No superinvestor reported holding RAPT at the end of Q4 2025.

Latest insider trades

See all insider trades

Open-market purchases and sales by RAPT Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 8, 2024 (view filing)Jan 53 daysBrockstedt Dirk G.CHIEF SCIENTIFIC OFFICERSSale−898$22.78−$20.5K−3.1%27.8K after
Dec 22, 2023 (view filing)Dec 211 dayHo WilliamChief Medical OfficerSSale−2.50K$21.68−$54.2K−14.3%15.0K after
Nov 29, 2023 (view filing)Nov 281 dayHo WilliamChief Medical OfficerSSale−1.50K$13.72−$20.6K−7.9%17.5K after
Oct 4, 2023 (view filing)Oct 31 dayHo WilliamChief Medical OfficerSSale−2.50K$15.77−$39.4K−11.7%18.8K after
Aug 22, 2023 (view filing)Aug 184 daysHo WilliamChief Medical OfficerSSale−2.50K$18.92−$47.3K−10.5%21.3K after
Apr 20, 2023 (view filing)Apr 191 dayHo WilliamChief Medical OfficerSSale−5.00K$18.88−$94.4K−19.2%21.0K after
Mar 15, 2023 (view filing)Mar 141 dayRobbins WendyeDirectorPPurchase+2.50K$18.99+$47.5K+20.2%14.9K after3 lots
Mar 15, 2023 (view filing)Mar 141 dayRobbins WendyeDirectorPPurchase+2.50K$20.05+$50.1K+62.5%6.50K after
Mar 13, 2023 (view filing)Mar 76 daysLateHo WilliamChief Medical OfficerSSale−5.00K$29.62−$148.1K−16.4%25.5K after
Jan 26, 2023 (view filing)Jan 242 daysHo WilliamChief Medical OfficerSSale−5.00K$30.00−$150.0K−14.3%30.1K after

Top 10 13F holders, Q4 2025

See all 106 holders

The largest institutional positions in RAPT Therapeutics, Inc. at the end of Q4 2025; share changes are against Q3 2025.

Institutions holding RAPT in Q4 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Medicxi Ventures Management (Jersey) Ltd2,794,000$94.6M11.33%00.0%Unchanged
TCG Crossover Management, LLC2,582,408$87.5M2.89%+946,133+57.8%Added
FCPM III Services B.V.1,833,333$62.1M8.14%+1,489,096+432.6%Added
OrbiMed Advisors LLC1,642,891$55.6M1.14%+556,273+51.2%Added
RTW Investments, LP1,637,165$55.5M0.56%+166,666+11.3%Added
Foresite Capital Management VI LLC1,562,500$52.9M16.00%00.0%Unchanged
Siren, L.L.C.1,375,000$46.6M1.39%+794,534+136.9%Added
Vanguard Group Inc1,186,791$40.2M0.00%+490,603+70.5%Added
Frazier Life Sciences Management, L.P.983,333$33.3M0.89%+983,333New
Braidwell LP929,694$31.5M1.01%+929,694New

Holders of 5% or more of RAPT

See all 8 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of RAPT Therapeutics, Inc..

Largest holders of RAPT from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Medicxi IV LP13G16.90%22.4M sharesNewJan 6, 20251 filingJan 6, 2025SEC
TCG Crossover GP II, LLC13G9.99%13.2M sharesNewJan 3, 20251 filingJan 3, 2025SEC
Redmile Group, LLC13G/A9.90%13.9M shares–Jun 3, 20224 filingsFeb 14, 2025SEC
Redmile Group, LLC13G/A9.90%1.77M shares–Aug 14, 20251 filingAug 14, 2025SEC
Foresite Capital Fund VI LP13G9.30%12.5M sharesNewDec 30, 20241 filingDec 30, 2024SEC